Serpa-Díaz, Dagoberto http://orcid.org/0000-0002-4827-7960
Llanos-Florez, Carlos A. http://orcid.org/0009-0007-6840-7682
Uribe, Ronald Serrano http://orcid.org/0009-0009-4848-1089
de Salazar, Dora I. Molina http://orcid.org/0000-0002-8006-915X
Giraldo-Gonzalez, German C. http://orcid.org/0000-0002-1737-2201
Urina-Triana, Miguel http://orcid.org/0000-0001-6003-4622
Suarez-Rodriguez, Andres F. http://orcid.org/0009-0004-6502-0819
Alzate-Vinasco, Maria A. http://orcid.org/0009-0006-6247-6049
Article History
Received: 7 February 2024
Accepted: 9 April 2024
First Online: 30 April 2024
Declarations
:
: The author(s) declared the following potential conflicts of interest concerning this article's research, authorship, and publication. Dagoberto Serpa-Díaz has acted as an advisor for Boehringer Ingelheim, received honoraria from Novo Nordisk, Pfizer, Boehringer Ingelheim, and Amgen, and received research funding from Novo Nordisk. Carlos A. Llanos-Florez has received honoraria from Novo Nordisk. German C Giraldo-Gonzalez has received honoraria from Novo Nordisk, Sanofi, Pfizer, Boehringer Ingelheim and Amgen. Andres F. Suarez-Rodriguez and Maria A. Alzate-Vinasco are Novo Nordisk employees. Ronald Serrano Uribe and, Dora I. Molina de Salazar has nothing to disclose.
: The ethical considerations for this protocol are based on the Declaration of Helsinki and the Ethical Guidelines for Health-Related Research with Human Beings prepared by the Council for International Organizations of Medical Sciences (CIOMS) in collaboration with the World Health Organization (WHO). The protocol was approved by all the institution’s ethics committees or Institution Review Board (IRB). This study complies with the Colombian Ministry of Health’s Resolution 8430 and was consider a no risk study and as such no participants’ consent to participate was required. No participants’ consent to publish was required because no identifiable information is presented in the results. Details from each center contribution and IRB approval are provided in the supplementary material.